INTRODUCTION:

Neurological disorders are highly challenging to treat because of their complexity and the restrictive blood-brain barrier (BBB), which limits the delivery of therapeutic agents to the central nervous system. Conditions such as Rett syndrome, Alzheimer's disease, Parkinson's disease, and multiple sclerosis particularly suffer from this issue, highlighting the need for innovative drug delivery strategies to enhance treatment effectiveness¹.

Rett syndrome (RTT) is a neurodevelopmental disorder that mainly affects females and is caused by mutations in the MECP2 gene. This gene is responsible for producing a protein critical in regulating gene expression in neurons^2,3. When the MECP2 malfunctions, it disrupts neuronal communication and function, resulting in symptoms such as developmental regression, loss of motor skills, and cognitive impairments. The blood-brain barrier (BBB) makes it difficult to discover effective treatments for Rett syndrome, thus the idea of employing Toxoplasma gondii as a medication delivery vector is particularly appealing. By genetically modifying the parasite to carry and deliver a functional MECP2 gene or protein, the approach seeks to restore normal gene expression and mitigate the symptoms of Rett syndrome⁴. This review covers the latest research on Toxoplasma gondii, examining its biological processes, its role in drug delivery systems for the management of Rett syndrome, and the challenges involved in its implementation.

LIMITATIONS OF CURRENT TREATMENTS:

Current treatments for Rett Syndrome (RTT) primarily focus on managing symptoms, as there is no cure available for this debilitating disorder. These therapies are often only partially effective and vary in their efficacy across patients. One of the major challenges in treating RTT is the difficulty in delivering therapeutic agents to the brain due to the blood-brain barrier (BBB), which prevents most drugs from reaching the central nervous system (CNS). While gene therapy offers hope, safely and effectively targeting the MECP2 gene to the appropriate neurons remains a significant hurdle, with current delivery mechanisms facing issues such as immune responses and inconsistent long-term expression⁴. Additionally, there are no treatments available that can modify the underlying disease process, and interventions often need to be applied early in development to have any significant impact. Moreover, the response to treatments can vary widely among patients, influenced by factors such as age, disease progression, and individual genetic variations. Supportive care, including physical, occupational, and speech therapies, requires long-term commitment and can be a significant burden for families, particularly given the variability in the availability and quality of care. These limitations highlight the pressing need for more innovative and effective treatment approaches for RTT, such as the exploration of novel drug delivery systems.

TOXOPLASMA GONDII:

Toxoplasma gondii is a widespread protozoan parasite that has a significant global impact, primarily due to its role in causing toxoplasmosis. This parasite infects a wide range of warm-blooded animals, including humans^5,6. T. gondii is best known for its ability to invade and persist within host cells, particularly in the central nervous system (CNS). One of the most remarkable features of T. gondii is its ability to cross biological barriers, including the blood-brain barrier (BBB), allowing it to establish long-term infections in the brain. Toxoplasma gondii can cause severe health issues in certain populations, particularly in immunocompromised individuals and during pregnancy, where it can lead to serious complications such as congenital toxoplasmosis^7,8. The parasite's ability to manipulate host behavior and its complex life cycle, involving both sexual reproduction in the intestines of cats and asexual reproduction in intermediate hosts (including humans), contribute to its persistence and widespread nature.

Figure 1.1: Structure of Toxoplasma gondii

Pathogenesis:

Toxoplasmosis is primarily acquired through the ingestion of tissue cysts found in undercooked meat or oocysts present in contaminated food or water. Once ingested, these hardy parasites traverse the intestinal wall, initiating a phase of rapid multiplication⁹. This initial stage often remains asymptomatic, but it can lead to localized inflammation and tissue damage within the intestines and nearby lymph nodes. Subsequently, the resilient parasite embarks on a systemic journey, spreading throughout the body via the bloodstream and lymphatic system. Its ability to invade and replicate within various cell types enables widespread dissemination. This invasive process can result in tissue damage, or necrosis, in multiple organs. Particularly vulnerable are vital organs such as the brain, heart, and adrenal glands. In individuals with compromised immune systems, the infection may transition from an acute to a chronic phase. The parasite can reactivate from latent cysts, leading to severe complications, most notably encephalitis characterized by the formation of multiple brain abscesses^10,11.

Sexual Life Cycle:

Cats serve as the definitive hosts for Toxoplasma gondii. When a cat ingests infected prey, the parasite undergoes sexual reproduction within the intestinal epithelium. This process involves the formation of male and female gametes, culminating in the production of oocysts. These oocysts are then shed in the cat's feces, contaminating the environment and initiating a new infectious cycle^12,13. A unique aspect of this process is the requirement of a specific enzyme, delta-6-desaturase, which is absent in cats. This enzyme deficiency leads to an accumulation of linoleic acid, a crucial factor enabling sexual reproduction in the parasite.

Figure 1.2: Life Cycle of Toxoplasma gondii

Asexual Life Cycle:

Toxoplasma gondii, a protozoan parasite, has a complex life cycle that includes several asexual stages, each playing a vital role in its propagation and survival within various hosts. Understanding these stages is essential for comprehending the parasite’s transmission dynamics and potential impacts on health¹⁴.

1. Tachyzoites: The life cycle begins with tachyzoites, the rapidly multiplying and motile forms of T. gondii. These parasites emerge when bradyzoites or sporozoites enter the host’s intestinal epithelium, generally following the ingestion of tissue cysts or oocysts. Tachyzoites are characterized by their ability to swiftly replicate and spread throughout the host’s body via the bloodstream, leading to acute infection. This phase is critical for the parasite’s initial expansion and establishment within the host.

2. Merozoites: After tachyzoites proliferate extensively, some differentiate into merozoites, particularly within the intestines of the definitive host, typically felines. When a cat consumes tissue cysts containing bradyzoites, these bradyzoites convert into merozoites inside intestinal epithelial cells. Merozoites also replicate rapidly, contributing to a significant increase in the parasite’s population before they undergo a transformation into sexual stages. This transition is essential for the eventual production of oocysts, which can then be shed in the cat’s feces, facilitating the parasite’s transmission to new hosts.

3. Bradyzoites: Bradyzoites represent the slow-dividing stage of T. gondii, residing within tissue cysts in various intermediate hosts, including rodents and humans. When a new host consumes these cysts, bradyzoites are released and migrate to intestinal epithelial cells, where they can reactivate and convert back into tachyzoites. This cyclical process allows the parasite to persist in the host for extended periods and can lead to chronic infection¹⁵.

Sporozoites are the stage of the parasite residing within oocysts. When a human or other warm-blooded host consumes an oocyst, sporozoites are released from it, infecting epithelial cells before converting to the proliferative tachyzoite stage.

MECHANISMS OF BLOOD-BRAIN BARRIER (BBB) PENETRATION:

The blood-brain barrier (BBB) poses a significant challenge in drug development for the central nervous system (CNS) because it restricts many therapeutic agents from entering the brain. This protective network of tightly packed endothelial cells effectively shields the brain from harmful substances while allowing essential nutrients and some lipid-soluble molecules to pass through. This protective mechanism is vital for brain health but it poses a significant challenge for drug delivery. Unlike its permeability to molecules like glucose and lipid-soluble compounds, the BBB restricts the passage of many therapeutic agents due to their poor lipid solubility and limited transport across the brain capillary endothelium. This restricted access results in suboptimal drug concentrations within the brain, hindering therapeutic efficacy. Even when drugs successfully cross the BBB, they encounter further obstacles within the brain environment, such as slow action, inefficient uptake by neuronal and brain cells, metabolic conversion into inactive forms, and binding to non-transporting proteins further complicate drug delivery and efficacy. The blood-brain barrier protects animals' brains by excluding large molecules and almost all proteins. This makes it challenging to deliver therapeutic proteins to the brain^16,17. However, Toxoplasma gondii, a parasite that can naturally cross the BBB and persist in the CNS, is being explored as a potential vector for delivering drugs directly to the brain. By leveraging its natural biological mechanisms, scientists are exploring the possibility of genetically engineering T. gondii to deliver therapeutic agents directly to the brain, offering a novel approach to treating neurological disorders such as Rett Syndrome. However, the use of a live pathogen as a therapeutic vector also presents significant challenges, including safety concerns, immune responses, and ensuring specificity in targeting the affected areas. These factors are critical considerations in the ongoing research into harnessing T. gondii for therapeutic applications. Toxoplasma gondii can enter the brain in two ways: directly breaching the blood-brain barrier (BBB) or through infected immune cells acting as a Trojan horse. Once inside the brain, the parasite can move independently or be carried by these infected cells. Interestingly, the enhanced movement of infected cells seen in other tissues is less pronounced in the brain. Infiltrating immune cells, particularly monocytes and CD8+ T cells, are crucial for spreading the parasite throughout the brain, as they transport T. gondii within blood vessels and brain tissue, facilitating wider dissemination. Research shows that both brain resident cells and immune cells can become infected, but immune cells, especially CD8+ T cells, carry a higher parasite load, indicating they might be more susceptible or supportive of parasite replication. These findings reveal the intricate relationship between T. gondii and the immune system, offering new insights into how the parasite spreads within the brain¹⁸.

Therapeutic Applications of Toxoplasma Gondii In Protein Delivery Across The Bbb:

Using Toxoplasma gondii as a vector to deliver proteins to the brain has several promising applications:

1. Parasite as a Drug Delivery System: T. gondii can be engineered to deliver therapeutic proteins directly to the brain, potentially overcoming the challenges posed by the blood-brain barrier (BBB) and improving the effectiveness of treatments for neurological diseases. This is particularly important given the challenges associated with delivering large and hydrophilic proteins across biological barriers¹⁹.

2. Potential Treatment for Rett Syndrome: The research highlighted the successful delivery of the MeCP2 protein, which is deficient in Rett syndrome, using Toxoplasma gondii as a vector. This approach highlights the potential of T. gondii for addressing Rett syndrome²⁰.

3. Implications for Other Diseases: This approach opens new possibilities for treating diseases linked to specific protein deficiencies or abnormalities, paving the way for future therapeutic innovations²¹.

4. Protein Replacement Therapies: T. gondii can be engineered to deliver therapeutic proteins that replace defective or missing proteins in various diseases. This is particularly relevant for monogenic diseases where a single protein deficiency leads to significant health issues. The ability to effectively deliver large proteins into neurons opens new avenues for treating neurological disorders²².

5. Gene Therapy: T. gondii can be utilized to deliver genome-editing proteins, such as CRISPR/Cas9 components, directly into target cells. This application is crucial for creating disease models and potentially correcting genetic defects in vivo, which could lead to innovative treatments for genetic disorders²³.

6. Cancer Therapy: The parasite could be adapted to deliver cytotoxic proteins or other therapeutic agents to brain tumors, potentially enhancing the targeting and efficacy of cancer treatments while minimizing systemic side effects.

7. Neurodegenerative Diseases: T. gondii could be used to deliver neuroprotective factors or enzymes that might slow down or reverse the progression of diseases such as Alzheimer’s or Parkinson’s by targeting and modifying specific brain pathways.

8. Combination Therapies: The ability of T. gondii to deliver multiple proteins simultaneously can facilitate combination therapies. This is particularly useful in cancer treatment, where delivering multiple therapeutic agents can enhance efficacy and reduce the likelihood of resistance.

9. Immunotherapy: T. gondii can be adapted to deliver engineered proteins that stimulate immune responses against tumors or infectious agents. This could lead to the development of novel immunotherapies that harness the body’s immune system to fight diseases more effectively.

10. Safety and Efficacy Improvements: Ongoing research aims to improve the safety and efficacy of T. gondii-based delivery systems. This includes exploring strain attenuation and developing methods to minimize potential adverse effects, which is crucial for clinical applications²⁴.

11. Research Tool: This system can serve as a valuable research tool to study the mechanisms of protein delivery and distribution within the brain, providing insights into how therapeutic proteins interact with brain cells and the overall impact on brain function.

Furthermore, the potential for T. gondii to be engineered for targeted delivery could revolutionize treatments for neurological disorders, allowing for localized therapy with minimal systemic side effects.

Engineering t. Gondii for Neuronal Protein Delivery:

Bracha S et al. (2023) investigated the use of Toxoplasma gondii rhoptries for secreting various neuronal proteins and their effects on host cell interactions. They engineered T. gondii to fuse Toxofilin with several neuronal proteins, including aspartoacylase (ASPA), survival of motor neuron 1 (SMN1), galactosyl ceramidase (GALC), parkin E3 ubiquitin ligase (PARK2), glial cell-derived neurotrophic factor (GDNF), methyl-CpG binding protein 2 (MECP2), and transcription factor EB (TFEB) and used fluorescence microscopy and Western blot analysis to evaluate the localization and expression levels of these fusion proteins. The study revealed that these fusion proteins, particularly GDNF, PARK2, and TFEB, localized to the rhoptry organelles, which is crucial for utilizing T. gondii as a delivery vector. The research highlighted that these proteins modulate host cell behavior and immune responses, potentially enhancing T. gondii survival and replication within the host environment. The study also showed that stable expression of the fusion proteins led to more consistent modulation of host pathways, suggesting potential therapeutic targets. Although many proteins localized to unexpected organelles, the successful localization of GDNF, PARK2, and TFEB to the rhoptries is promising for therapeutic applications. The study confirmed the delivery of MeCP2 into neurons, demonstrating efficient protein delivery throughout the brain following intraperitoneal administration in mice. These findings suggest that manipulating protein localization and enhancing secretion could improve T. gondii 's therapeutic potential for targeted drug delivery²⁴.

Figure 1: Engineered Toxoplasma gondii for Neuronal Protein Delivery

ROUTES OF ADMINISTRATION OF TOXOPLASMA GONDII:

To effectively utilize Toxoplasma gondii vectors for protein delivery in the treatment of Rett Syndrome, a range of administration strategies must be evaluated to optimize therapeutic outcomes.

Table 1: Route of Administration of Toxoplasma gondii:

S. No.	Route of Administration	Method	Advantages	Considerations
1	Intranasal Administration	The vector is delivered via the nasal cavity	This route can leverage the olfactory and trigeminal nerves to transport the vector to the brain, bypassing the blood-brain barrier.	Ensuring effective delivery and stability of the vector in the nasal environment.
2	Intravenous Injection	The vector is administered into the bloodstream	Systemic delivery allows the vector to circulate throughout the body and potentially cross the blood-brain barrier.	Requires efficient crossing of the BBB and targeted delivery within the central nervous system.
3	Intracerebral Injection	The vector is injected directly into specific regions of the brain	Provides precise delivery to targeted brain areas affected by Rett Syndrome.	Invasive procedure that may involve surgical techniques for accurate placement.
4	Intraventricular Injection	The vector is administered into the cerebrospinal fluid within the brain's ventricles.	Facilitates widespread distribution throughout the central nervous system.	Requires careful management of injection to avoid complications.
5	Intrathecal Injection	The vector is injected into the spinal canal or subarachnoid space.	Allows for distribution of the vector along the spinal cord and potentially to the brain.	Technique involves accessing the spinal canal, which may carry risks.
6.	Convection-Enhanced Delivery	The vector is infused into targeted brain regions using pressure-driven techniques.	Enhances distribution and penetration of the vector in specific brain areas.	Requires specialized equipment and expertise
7	Microinjection	The vector is delivered at a cellular or tissue level using fine needles	Allows for very precise targeting of specific neurons or brain regions	Highly specialized technique with potential for localized delivery

Each administration route presents unique advantages and challenges. The choice of administration route depends on factors such as the target area in the brain, the nature of the protein being delivered, and the overall treatment strategy for Rett Syndrome²⁵.

CHALLENGES AND RISKS ASSOCIATED WITH TOXOPLASMA GONDII:

Utilizing Toxoplasma gondii as a live pathogen for drug delivery to the brain presents several significant challenges and risks. One major concern is the potential for these organisms to establish persistent infections, which could reactivate latent diseases and provoke unintended immune responses. Their capacity to manipulate the host’s immune system might exacerbate existing health conditions such as cancer or metabolic disorders, complicating both treatment and recovery^26,27. Safety is a primary concern, as the use of a live pathogen introduces risks such as potential pathogenicity and unintended side effects²⁸. It is essential to ensure that genetically modified T. gondii does not cause disease or adverse effects in patients. Moreover, the host's immune response poses a significant challenge; T. gondii may be recognized as a threat, potentially triggering an immune reaction that could reduce the therapeutic efficacy or cause inflammatory responses^29,30. Specificity in drug delivery is another critical issue, requiring precise control over the parasite’s behavior to ensure accurate delivery of therapeutic agents to the intended brain cells or tissues, while avoiding off-target effects. Chronic inflammation, resulting from prolonged parasite presence, can increase the risk of developing non-communicable diseases such as heart disease, diabetes, and certain cancers^31,32. While there is promise in using parasites to modulate the immune system for therapeutic purposes, our understanding of these mechanisms remains limited. Therefore, the potential benefits of using T. gondii must be carefully balanced against the risks of infection, immune dysregulation, and chronic inflammation. Addressing these challenges is crucial for developing a safe and effective therapeutic system that leverages T. gondii as a delivery vector.

FUTURE DIRECTIONS:

Future directions for utilizing Toxoplasma gondii as a vector for targeted drug delivery in Rett Syndrome involve several key areas of research and development. Advancements in genetic engineering are crucial for optimizing the vector's efficiency and specificity, including enhancing methods for precise gene insertion and ensuring stable expression while addressing biosafety concerns. Improving targeted delivery mechanisms is another important focus, where enhancing the vector's ability to target specific neuronal cells and exploring combination therapies with gene editing tools or small molecules could significantly impact therapeutic outcomes. Extensive preclinical studies are necessary to evaluate the efficacy, safety, and pharmacokinetics of Toxoplasma gondii -based delivery systems, paving the way for clinical trials while navigating regulatory and ethical considerations. Additionally, understanding the mechanisms of delivery and host-parasite interactions can help minimize off-target effects and improve efficacy. Personalized therapies tailored to individual genetic profiles of Rett Syndrome patients and addressing public perception and ethical concerns are also vital for advancing this approach. Collectively, these future directions aim to refine and validate Toxoplasma gondii as a promising tool for targeted drug delivery in Rett Syndrome.

CONCLUSION:

The exploration of Toxoplasma gondii as a vector for targeted drug delivery in Rett Syndrome represents a promising yet complex frontier in therapeutic development. This review highlights the unique advantages of using this neurotropic parasite, particularly its ability to cross the blood-brain barrier and deliver therapeutic agents directly to the central nervous system. While the potential for innovative treatments is significant, the approach also presents substantial challenges, including safety concerns, immune responses, and the need for precise targeting. Advances in genetic engineering and delivery mechanisms are crucial to overcoming these obstacles and improving the efficacy of Toxoplasma gondii-based therapies. Future research should focus on optimizing vector engineering, refining administration methods, and conducting comprehensive preclinical and clinical evaluations. Addressing these areas will be essential to harnessing the full therapeutic potential of Toxoplasma gondii and providing a new avenue for treating Rett Syndrome. By carefully navigating these challenges and leveraging emerging technologies, this approach could revolutionize the treatment landscape for Rett Syndrome and other neurological disorders.

REFERENCES:

1. Nance, E., Pun, S.H., Saigal, R. Drug delivery to the central nervous system. Nature Reviews Materials. 2022; 7(1): 314–331. https://doi.org/10.1038/s41578-021-00394-w

2. Good KV, Vincent JB, Ausió J. MeCP2: The Genetic Driver of Rett Syndrome Epigenetics. Front Genet. 2021; 12: 620859. doi: 10.3389/fgene.2021.620859. PMID: 33552148; PMCID: PMC7859524.

3. Minnu EM, Joslin J. RETT Syndrome: A Case Report. Research Journal of Science and Technology. 2022; 14(3):161-4.

4. Terstappen, G.C., Meyer, A.H., Bell, R.D. Strategies for delivering therapeutics across the blood–brain barrier. Nature Reviews Drug Discovery. 2021; 20: 362–383. https://doi.org/10.1038/s41573-021-00139-y

5. Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018; 8(2): 170216. doi: 10.1098/rsob.170216. PMID: 29445033; PMCID: PMC5830535.

6. Qudus WJ., Haider SK. The relation of Toxoplasma gondii with Tumor Necrotizing Factor-α in type II Diabetic patients. Research J. Pharm. and Tech. 2019; 12(10): 4817-4821.

7. S Al-Malki E. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci. 2021; 28(1): 962-969. doi: 10.1016/j.sjbs.2020.11.007. Epub 2020 Nov 11. PMID: 33424388; PMCID: PMC7783816.

8. Rita NN. Rammo. Bactericidal and Anti-biofilm Formation of Aqueous Plant Extracts against Pathogenic Bacteria. Asian J. Pharm. Res. 2017; 7(1): 25-29.

9. Kadbhane A.S, Dahikar S.B, Bhutada S.A. Antimicrobial Photodynamic Therapy – A Promising Approach to Control Pathogens and Infectious Skin Diseases. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(2):147-4.

10. Mendez OA, Koshy AA. Toxoplasma gondii: Entry, association, and physiological influence on the central nervous system. PLoS Pathog. 2017; 13(7): e1006351. doi: 10.1371/journal.ppat.1006351. PMID: 28727854; PMCID: PMC5519211.

11. Singariya P, Mourya KK, Kumar P. Estimation of Antibacterial Efficacy in Alkaloids of Anogeissus rotundifolia an Indigenous Medicinal Plant against Some Pathogenic Micro-organisms. Asian J. Research Chem. 2018; 11(2):432-440.

12. Poulin R. Parasite Manipulation of host behavior: An update and frequently asked questions. Advances in the study of Behavior. 2010; 41: 151-186. https://doi.org/10.1016/S0065-3454(10)41005-0

13. Dubey JP. Toxoplasma Gondii. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 84. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7752/.

14. English ED, Striepen B. The cat is out of the bag: How parasites know their hosts. PLoS Biol. 2019; 17(9): e3000446. doi: 10.1371/journal.pbio.3000446. PMID: 31487278; PMCID: PMC6748446.

15. Hatam-Nahavandi, K., Calero-Bernal, R., Rahimi, M.T. Toxoplasma gondii infection in domestic and wild felids as public health concerns: a systematic review and meta-analysis. Sci Rep. 2021; 11: 9509. https://doi.org/10.1038/s41598-021-89031-8.

16. Rekha Kumari. Baby Brain or Pregnancy Brain or Momnesia. Int. J. Nur. Edu. and Research. 2019; 7(1): 115-118.

17. Sanchez SG, Besteiro S. The pathogenicity and virulence of Toxoplasma gondii. Virulence. 2021; 12(1): 3095-3114. doi: 10.1080/21505594.2021.2012346. PMID: 34895084; PMCID: PMC8667916.

18. Jones, E. J., Korcsmaros, T., and Carding, S. R. Mechanisms and pathways of Toxoplasma gondii transepithelial migration. Tissue Barriers. 2017; 5(1). https://doi.org/10.1080/21688370.2016.1273865

19. Harris WJ, Asselin MC, Hinz R, Parkes LM, Allan S, Schiessl I, Boutin H, Dickie BR. In vivo methods for imaging blood-brain barrier function and dysfunction. Eur J Nucl Med Mol Imaging. 2023; 50(4): 1051-1083. doi: 10.1007/s00259-022-05997-1. Epub 2022 Nov 28. PMID: 36437425; PMCID: PMC9931809.

20. Namrata Negi. Rett Syndrome. International Journal of Nursing Education and Research. 2023; 11(2):180-2.

21. Schneider CA, Figueroa Velez DX, Orchanian SB, Shallberg LA, Agalliu D, Hunter CA, Gandhi SP, Lodoen MB. Toxoplasma gondii Dissemination in the Brain Is Facilitated by Infiltrating Peripheral Immune Cells. mBio. 2022; 13: e02838-22. https://doi.org/10.1128/mbio.02838-22

22. Ross EC, Olivera GC, Barragan A. Early passage of Toxoplasma gondii across the blood-brain barrier. Trends Parasitol. 2022; 38(6): 450-461. doi: 10.1016/j.pt.2022.02.003. Epub 2022 Feb 25. PMID: 35227615.

23. Jung BK, Pyo KH, Shin KY, Hwang YS, Lim H, Lee SJ, Moon JH, Lee SH, Suh YH, Chai JY, Shin EH. Toxoplasma gondii infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer's disease. PLoS One. 2012; 7(3): e33312. doi: 10.1371/journal.pone.0033312. Epub 2012 Mar 21. PMID: 22470449; PMCID: PMC3310043.

24. Carruthers VB. Armed and dangerous: Toxoplasma gondii uses an arsenal of secretory proteins to infect host cells. Parasitol Int. 1999; 48(1): 1-10. doi: 10.1016/s1383-5769(98)00042-7. PMID: 11269320.

25. Koshy AA, Fouts AE, Lodoen MB, Alkan O, Blau HM, Boothroyd JC. Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions. Nat Methods. 2010; 7(4): 307-9. doi: 10.1038/nmeth.1438. Epub 2010 Mar 7. PMID: 20208532; PMCID: PMC2850821.

26. Bracha S, Johnson HJ, Pranckevicius NA, Catto F, Economides AE, Litvinov S, Hassi K, Rigoli MT, Cheroni C, Bonfanti M, Valenti A, Stucchi S, Attreya S, Ross PD, Walsh D, Malachi N, Livne H, Eshel R, Krupalnik V, Levin D, Cobb S, Koumoutsakos P, Caporale N, Testa G, Aguzzi A, Koshy AA, Sheiner L, Rechavi O. Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons. Nat Microbiol. 2024; 9(8): 2051-2072. doi: 10.1038/s41564-024-01750-6. Epub 2024 Jul 29. PMID: 39075233; PMCID: PMC11306108.

27. Narava SSS, Kucherlapati S, Mugada VK, Yarguntla SR. A Review on Rett Syndrome: A Debilitating Neurodevelopmental Disorder. Research Journal of Pharmacology and Pharmacodynamics. 2023; 15(4):159-4.

28. A. Rajeswari, S. Ramesh. Investigations on pharmacological constituent and antimicrobial efficacy of plant diffusate against clinical pathogens. Research J. Pharm. and Tech. 5(12): Dec. 2012; Page 1518-1524.

29. Sreeja. M.K, Gowrishankar N.L, Adisha. S, Divya. K.C. Antibiotic Resistance-Reasons and the Most Common Resistant Pathogens – A Review. Research J. Pharm. and Tech. 2017; 10(6): 1886-1890.

30. Matta, S.K., Rinkenberger, N., Dunay, I.R. Toxoplasma gondii infection and its implications within the central nervous system. Nat Rev Microbiol. 2021; 19: 467–480. https://doi.org/10.1038/s41579-021-00518-7

31. Oliveira FMS, Cruz RE, Pinheiro GRG, Caliari MV. Comorbidities involving parasitic diseases: A look at the benefits and complications. Exp Biol Med (Maywood). 2022; 247(20): 1819-1826. doi: 10.1177/15353702221108387. Epub 2022 Jul 23. PMID: 35876147; PMCID: PMC9679356.

32. Wu Y, Duffey M, Alex SE, Suarez-Reyes C, Clark EH, Weatherhead JE. The role of helminths in the development of non-communicable diseases. Front Immunol. 2022; 13: 941977. doi: 10.3389/fimmu.2022.941977. PMID: 36119098; PMCID: PMC9473640.

Received on 17.04.2025 Revised on 28.05.2025

Accepted on 30.06.2025 Published on 22.07.2025

Available online from July 26, 2025

Res.J. Pharmacology and Pharmacodynamics.2025;17(3):206-212.

DOI: 10.52711/2321-5836.2025.00034

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.